Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

NCT00180895 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Burkitt Lymphoma

Interventions

DRUG: Rituximab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]